Reumatizam, Vol. 64 No. suppl. 1, 2017.
Review article
TREATMENT OF PSORIATIC ARTHRITIS WITH BIOLOGICAL AND TARGETED SYNTHETIC DRUGS
Branimir Anić
Ivan Padjen
Abstract
Treatment options in psoriatic arthritis have tremendously evolved in the new millennium. Th e advent of biological
agents has opened the door to more successful treatment of all domains of psoriatic arthritis, including peripheral
and axial arthritis, dactylitis, enthesitis, psoriasis, and nail disease. Despite the important step forward represented
by the introduction of TNF-α inhibitors, the failure to achieve an ACR20 response in about 40% of patients was a clear
signal that further therapeutic options should be sought. Th ree new biologicals – ustekinumab, secukinumab, and
ixekizumab – as well as the novel targeted synthetic small-molecule agent apremilast have received approval for psoriatic
arthritis within the last four years, expanding the therapeutic armamentarium. Herein, we provide an overview
of the existing options for the treatment of psoriatic arthritis with biological and targeted synthetic drugs, as well as
their role in the recent treatment recommendations.
Keywords
Arthritis, psoriatic – drug therapy; Tumor necrosis factor – alpha – antagonist and inhibitors; Ustekinumab – therapeutic use; Antibodies, monoclonal – therapeutic use; Th alidomide – analogs and derivatives, therapeutic use; Phosphodiesterase 4 inhibitors – therapeutic use; Biological products – therapeutic use
Hrčak ID:
188339
URI
Publication date:
25.10.2017.
Visits: 4.108 *